Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy

a longitudinal multicenter study in a non-endemic area

A. Cortese, G. Vita, M. Luigetti, M. Russo, G. Bisogni, M. Sabatelli, F. Manganelli, L. Santoro, T. Cavallaro, G. M. Fabrizi, A. Schenone, M. Grandis, C. Gemelli, A. Mauro, L. G. Pradotto, L. Gentile, C. Stancanelli, A. Lozza, S. Perlini, G. Piscosquito & 4 others D. Calabrese, A. Mazzeo, L. Obici, D. Pareyson

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects had the common Val30Met mutation, mean age of onset was remarkably late (59 years) and 18 % was in advanced disease stage at study entry. Tafamidis proved safe and well-tolerated. One-third of patients did not show significant progression along 36 months, independently from mutation type and disease stage. Neurological function worsened particularly in the first 6 months but progression slowed significantly thereafter. Autonomic function remained stable in 33 %, worsened in 56 % and improved in 10 %. Fifteen percent of patients showed cardiac disease progression and 30 % new onset of cardiomyopathy. Overall, Tafamidis was not able to prevent functional progression of the disease in 23 (43 %) subjects, including 16 patients who worsened in their walking ability and 12 patients who reached a higher NYHA score during the follow-up period. A higher mBMI at baseline was associated with better preservation of neurological function. In conclusion, neuropathy and cardiomyopathy progressed in a significant proportion of patients despite treatment. However, worsening of neurological function slowed after the first 6 months and also subjects with more advanced neuropathy, as well as patients with non-Val30Met mutation, benefited from treatment. Body weight preservation is an important favorable prognostic factor.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Neurology
DOIs
Publication statusAccepted/In press - Mar 16 2016

Fingerprint

Italy
Multicenter Studies
Longitudinal Studies
Safety
Mutation
Prealbumin
Cardiomyopathies
Disease Progression
tafamidis
Amyloidosis, Hereditary, Transthyretin-Related
Age of Onset
Walking
Observational Studies
Heart Diseases
Body Weight
Therapeutics

Keywords

  • Amyloid polyneuropathy
  • Tafamidis
  • Transthyretin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy : a longitudinal multicenter study in a non-endemic area. / Cortese, A.; Vita, G.; Luigetti, M.; Russo, M.; Bisogni, G.; Sabatelli, M.; Manganelli, F.; Santoro, L.; Cavallaro, T.; Fabrizi, G. M.; Schenone, A.; Grandis, M.; Gemelli, C.; Mauro, A.; Pradotto, L. G.; Gentile, L.; Stancanelli, C.; Lozza, A.; Perlini, S.; Piscosquito, G.; Calabrese, D.; Mazzeo, A.; Obici, L.; Pareyson, D.

In: Journal of Neurology, 16.03.2016, p. 1-9.

Research output: Contribution to journalArticle

Cortese, A, Vita, G, Luigetti, M, Russo, M, Bisogni, G, Sabatelli, M, Manganelli, F, Santoro, L, Cavallaro, T, Fabrizi, GM, Schenone, A, Grandis, M, Gemelli, C, Mauro, A, Pradotto, LG, Gentile, L, Stancanelli, C, Lozza, A, Perlini, S, Piscosquito, G, Calabrese, D, Mazzeo, A, Obici, L & Pareyson, D 2016, 'Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area', Journal of Neurology, pp. 1-9. https://doi.org/10.1007/s00415-016-8064-9
Cortese, A. ; Vita, G. ; Luigetti, M. ; Russo, M. ; Bisogni, G. ; Sabatelli, M. ; Manganelli, F. ; Santoro, L. ; Cavallaro, T. ; Fabrizi, G. M. ; Schenone, A. ; Grandis, M. ; Gemelli, C. ; Mauro, A. ; Pradotto, L. G. ; Gentile, L. ; Stancanelli, C. ; Lozza, A. ; Perlini, S. ; Piscosquito, G. ; Calabrese, D. ; Mazzeo, A. ; Obici, L. ; Pareyson, D. / Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy : a longitudinal multicenter study in a non-endemic area. In: Journal of Neurology. 2016 ; pp. 1-9.
@article{05e3418a86424bf1afb138e6c5ea29a5,
title = "Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area",
abstract = "Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 {\%} of enrolled subjects had the common Val30Met mutation, mean age of onset was remarkably late (59 years) and 18 {\%} was in advanced disease stage at study entry. Tafamidis proved safe and well-tolerated. One-third of patients did not show significant progression along 36 months, independently from mutation type and disease stage. Neurological function worsened particularly in the first 6 months but progression slowed significantly thereafter. Autonomic function remained stable in 33 {\%}, worsened in 56 {\%} and improved in 10 {\%}. Fifteen percent of patients showed cardiac disease progression and 30 {\%} new onset of cardiomyopathy. Overall, Tafamidis was not able to prevent functional progression of the disease in 23 (43 {\%}) subjects, including 16 patients who worsened in their walking ability and 12 patients who reached a higher NYHA score during the follow-up period. A higher mBMI at baseline was associated with better preservation of neurological function. In conclusion, neuropathy and cardiomyopathy progressed in a significant proportion of patients despite treatment. However, worsening of neurological function slowed after the first 6 months and also subjects with more advanced neuropathy, as well as patients with non-Val30Met mutation, benefited from treatment. Body weight preservation is an important favorable prognostic factor.",
keywords = "Amyloid polyneuropathy, Tafamidis, Transthyretin",
author = "A. Cortese and G. Vita and M. Luigetti and M. Russo and G. Bisogni and M. Sabatelli and F. Manganelli and L. Santoro and T. Cavallaro and Fabrizi, {G. M.} and A. Schenone and M. Grandis and C. Gemelli and A. Mauro and Pradotto, {L. G.} and L. Gentile and C. Stancanelli and A. Lozza and S. Perlini and G. Piscosquito and D. Calabrese and A. Mazzeo and L. Obici and D. Pareyson",
year = "2016",
month = "3",
day = "16",
doi = "10.1007/s00415-016-8064-9",
language = "English",
pages = "1--9",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy

T2 - a longitudinal multicenter study in a non-endemic area

AU - Cortese, A.

AU - Vita, G.

AU - Luigetti, M.

AU - Russo, M.

AU - Bisogni, G.

AU - Sabatelli, M.

AU - Manganelli, F.

AU - Santoro, L.

AU - Cavallaro, T.

AU - Fabrizi, G. M.

AU - Schenone, A.

AU - Grandis, M.

AU - Gemelli, C.

AU - Mauro, A.

AU - Pradotto, L. G.

AU - Gentile, L.

AU - Stancanelli, C.

AU - Lozza, A.

AU - Perlini, S.

AU - Piscosquito, G.

AU - Calabrese, D.

AU - Mazzeo, A.

AU - Obici, L.

AU - Pareyson, D.

PY - 2016/3/16

Y1 - 2016/3/16

N2 - Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects had the common Val30Met mutation, mean age of onset was remarkably late (59 years) and 18 % was in advanced disease stage at study entry. Tafamidis proved safe and well-tolerated. One-third of patients did not show significant progression along 36 months, independently from mutation type and disease stage. Neurological function worsened particularly in the first 6 months but progression slowed significantly thereafter. Autonomic function remained stable in 33 %, worsened in 56 % and improved in 10 %. Fifteen percent of patients showed cardiac disease progression and 30 % new onset of cardiomyopathy. Overall, Tafamidis was not able to prevent functional progression of the disease in 23 (43 %) subjects, including 16 patients who worsened in their walking ability and 12 patients who reached a higher NYHA score during the follow-up period. A higher mBMI at baseline was associated with better preservation of neurological function. In conclusion, neuropathy and cardiomyopathy progressed in a significant proportion of patients despite treatment. However, worsening of neurological function slowed after the first 6 months and also subjects with more advanced neuropathy, as well as patients with non-Val30Met mutation, benefited from treatment. Body weight preservation is an important favorable prognostic factor.

AB - Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects had the common Val30Met mutation, mean age of onset was remarkably late (59 years) and 18 % was in advanced disease stage at study entry. Tafamidis proved safe and well-tolerated. One-third of patients did not show significant progression along 36 months, independently from mutation type and disease stage. Neurological function worsened particularly in the first 6 months but progression slowed significantly thereafter. Autonomic function remained stable in 33 %, worsened in 56 % and improved in 10 %. Fifteen percent of patients showed cardiac disease progression and 30 % new onset of cardiomyopathy. Overall, Tafamidis was not able to prevent functional progression of the disease in 23 (43 %) subjects, including 16 patients who worsened in their walking ability and 12 patients who reached a higher NYHA score during the follow-up period. A higher mBMI at baseline was associated with better preservation of neurological function. In conclusion, neuropathy and cardiomyopathy progressed in a significant proportion of patients despite treatment. However, worsening of neurological function slowed after the first 6 months and also subjects with more advanced neuropathy, as well as patients with non-Val30Met mutation, benefited from treatment. Body weight preservation is an important favorable prognostic factor.

KW - Amyloid polyneuropathy

KW - Tafamidis

KW - Transthyretin

UR - http://www.scopus.com/inward/record.url?scp=84961207014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961207014&partnerID=8YFLogxK

U2 - 10.1007/s00415-016-8064-9

DO - 10.1007/s00415-016-8064-9

M3 - Article

SP - 1

EP - 9

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -